Akèy › Maladi fwa steatotik › Arizona
Etid klinik pou Maladi fwa steatotik nan Arizona
14 etid pou Maladi fwa steatotik ap chèche patisipan nan sit nan Arizona.
Vil nan Arizona
Tèks ofisyèl etid la (Anglè)
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
- Arizona Liver Health - Tucson, Tucson
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT07527910Early Tracking of Childhood Health Determinants (ETCHED) Study
- NIDDK, Phoenix, Phoenix
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
1 Day – 99 Years · Tout sèks · Mizajou Sep 28, 2026 · NCT03481829A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- Arizona Liver Health, Chandler
- The Institute for Liver Health II LLC DBA Arizona Liver Health - Peoria, Peoria
- Adobe Clinical Research, Tucson
- ak 2 plis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- The Institute for Liver Health II dba Arizona Clinical Trials - Chandler, Chandler
- Spectrum Research Institute, Gilbert
- The Institute for Liver Health II dba Arizona Liver Health - Peoria, Peoria
- ak 3 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Chandler
- Akero Clinical Study Site, Peoria
- Akero Clinical Study Site, Scottsdale
- ak 4 plis
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Sep 21, 2026 · NCT06528314A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Arizona Liver Health, Chandler
- Arizona Liver Health - Peoria, Peoria
- Adobe Clinical Research, LLC, Tucson
- ak 1 plis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 9, 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Chandler
- 89bio Clinical Study Site, Glendale
- 89bio Clinical Study Site, Sun City
- ak 2 plis
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Sep 3, 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Chandler
- 89bio Clinical Study Site, Peoria
- 89bio Clinical Study Site, Phoenix
- ak 4 plis
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 3, 2026 · NCT06419374A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Chandler
- GSK Investigational Site, Phoenix
- GSK Investigational Site, Tucson
- ak 1 plis
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Aug 3, 2026 · NCT06613698Fibrosis Lessens After Metabolic Surgery
- Banner Health Center, Phoenix
Ap rekriteFaz 4Volontè an sante akeyi
Laj 18 a 75 · Tout sèks · Mizajou Jul 31, 2026 · NCT06374875A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Chandler
- GSK Investigational Site, Tucson
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Jul 27, 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Chandler
- GSK Investigational Site, Mesa
- GSK Investigational Site, Tucson
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Jul 8, 2026 · NCT06920043Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- Arizona Liver Health, Chandler
Ap rekrite
Laj 18 a 75 · Tout sèks · Mizajou May 19, 2026 · NCT04054310Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
- Mayo Clinic in Arizona, Scottsdale
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 30 a 70 · Tout sèks · Mizajou Jan 28, 2026 · NCT04232566Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.